This $64 Million Cannabis Landlord is Cashing Fat Rent Checks

Posted on by The INO.com Team

Analysis originally distributed on January 18, 2017 By: Michael Vodicka of Cannabis Stock Trades

Investing in real estate has been one of the best ways to get wealthy in the United States for the last 100 years.

In Forbes' 2016 list of the 400 richest people in America, real estate ranks as the sixth most common source of wealth.

This is just one more reason I am bullish on a new cannabis stock I like to call The Cannabis Landlord.

Innovative Industrial Properties (NYSE:IIPR) is a fresh face in the cannabis stock sector.

This undercover cannabis stock caught my attention for three reasons. Continue reading "This $64 Million Cannabis Landlord is Cashing Fat Rent Checks" →

Preview Issue #9: Theranos Layoffs, Amgen Wins and Potential Obamacare Repeal

Posted on by Noah Kiedrowski

INO Health & Biotech Stock Guide

Preview Issue #9 - January 25, 2017

BIOTECH, HEALTH & PHARMA NEWS

2017 is kicking off to be an eventful year in the healthcare space. Regeneron was handed a devastating blow in federal court in a lawsuit filed by Amgen surrounding its cholesterol-lowering drug Praluent. Amgen claimed that Regeneron’s Praluent infringed on Amgen’s patents and competing drug Repatha in a long-standing patent lawsuit. Amgen previously won a trial in which Regeneron was shown to have infringed on two patents covering a class of cholesterol-lowering drugs. The most recent ruling stipulates that Regeneron must stop selling Praluent in the U.S. altogether due to “irreparable harm” to Amgen. It’s extremely rare to see a ruling in which a drug is ordered to be removed from the market as opposed to a financial penalty or royalties. Monetary implications at the moment are minor as Praluent and Repatha have had minimal sales through the first 9 months of 2016 of $75 million and $83 million, respectively. Despite these numbers, if positive data comes to fruition that extends a clinical benefit to more patients in lowering rates of heart attacks, strokes and death then Amgen’s drug could gain broader insurance coverage and ultimately sell $2-$4 billion on an annual basis worldwide. Amgen shares popped 5% on the news while Regeneron shares sank 6% albeit shares were halted once the ruling came down.

WHAT'S NEXT

Continue reading "Preview Issue #9: Theranos Layoffs, Amgen Wins and Potential Obamacare Repeal" →

Did The Markets Overreact - Again - To Yellen's Remarks?

Posted on by George Yacik

George Yacik - INO.com Contributor - Fed & Interest Rates


You may not have noticed it, but before last Wednesday the bond market had been in kind of a mini-rally for the previous month. On Tuesday, the benchmark 10-year Treasury note fell to 2.32%, its lowest level since the end of November. That was down from 2.60% in mid-December, which also happened to be its highest mark since 2014.

But by the end of the week the yield on the 10-year had jumped back up to 2.47%, up 15 basis points in just three days. What happened to put the brakes so suddenly on this rally? Why, Janet Yellen spoke, and when Janet Yellen speaks – well, you know the rest.

But did anyone really listen? Continue reading "Did The Markets Overreact - Again - To Yellen's Remarks?" →

Stocks Head Lower As Trump Anxiety Grows

Posted on by The INO.com Team

Hello MarketClub members everywhere. Stocks and the U.S. Dollar are falling as President Donald Trump promised a "very major" border tax and signed an executive order on Monday to withdraw the U.S. from the Trans-Pacific Partnership (TPP) trade deal and all indications are that he will sign an order to renegotiate the North American Free Trade Agreement (NAFTA) as he begins his reworking of America's trade relationships.

Most investors are also awaiting further details on the new president's plans to boost government spending before jumping back in the market. Are you one of the investors waiting?

MarketClub's Mid-day Market Report

Key levels to watch next week: Continue reading "Stocks Head Lower As Trump Anxiety Grows" →

Is Stillwater Mining Company (NYSE:SWC) A Smart Takeover?

Posted on by Aibek Burabayev

Aibek Burabayev - INO.com Contributor - Metals


Back in September, I wrote that the Stillwater Mining’s stock price was under pressure amid a weakening Platinum. The metal’s price action signaled that another drop below $1000 was in the cards. Indeed the metal price has lost “one digit” sinking to a low of $890 last month from the $1030 level when I wrote the post.

Stillwater Mining Company (NYSE:SWC) followed the metal’s drop and fell from $12.43 to $11.19 last October, but then it started to rocket higher and hit the 2-year maximum at the $17.50 level last December despite the new low in the platinum price. The clear answer to this contradiction in the metal and stock price behavior came on the 9th of December, 2016. That day, “The Last Mohican” of pure American platinum-group metals (PGM) producers announced that it would be acquired by a South African company for $2.2 billion in a deal that requires U.S. government approval. The purchase price was set at $18 per share and this explains the robust growth of the stock price on the market. Continue reading "Is Stillwater Mining Company (NYSE:SWC) A Smart Takeover?" →